1 / 45

IN THE NAME OF GOD

IN THE NAME OF GOD. Definition. Aplastic anemia is a clinical syndromemanifested as a deficiency: red cells, neutrophils monocytes and platelets in the blood fatty replacement of the marrow with a near absence of hematopoietic precursor cells. ETIOLOGIC CLASSIFICATION. Acquired Inherited.

flavio
Download Presentation

IN THE NAME OF GOD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. IN THE NAME OF GOD

  2. Definition • Aplastic anemia is a clinical syndromemanifested as a deficiency: • red cells, neutrophils monocytes and platelets in the blood • fatty replacement of the marrow with a near absence of hematopoietic precursor cells

  3. ETIOLOGIC CLASSIFICATION • Acquired • Inherited

  4. Acquired Aplastic Anemia Acquired aplastic anemia can occur in any age group and is usuallythe consequence of an autoimmune attakagainsthematopoieticstem cells

  5. These inherited disorders can masqueradeas acquired aplastic anemia • rarely respond toimmunosuppressive therapies • management usually consists ofsupportive care or bone marrow transplantation in severe cases

  6. Aplastic anemia most commonly presents between the ages of15 and 25 • There is a second smaller peak in incidence afterage 60

  7. Etiologic Aplastic Anemia • Idiopathic • Toxin and benzene • Drugs • Viruses • Pregnancy • Radiation

  8. Although aplastic anemia has beencausally associated with many agents including drugs benzeneexposure insecticides and viruses • No etiologic agent can be identifiedin most cases • A

  9. Benzene • Howeverrigorous epidemiologic study supporting an association between environmental toxins andaplastic anemia are lacking

  10. RADIATION • Ionizing radiation is directly toxic to bone marrow stem/progenitorcells • high doses (> 1.5 Gy to the whole body) can lead tosevere pancytopenia within 2 to 4 weeks after exposure • the LDsohas been estimated at about 4.5 Gy and a dose of lOGy or greateris thought to have 100% mortality

  11. Classification of most commonly drugs causing Aplastic Anemia Nonsteroidal analgestic • Phenylbutazone,indomethacin,ibuprofen,sulindac piroxicam diclofenac Anticonvulsant: • Hydantoin carbamazepine phenacemid Antibiotic • Sulfonamides chloramphenicol Antiprotozoal • Quinacrine chloroquine Antithyroid • Methimazol propylthiouracil Gold

  12. Most cases of druginducedaplastic anemia lead to an idiosyncratic immuneresponse directed against hematopoietic stem cells and are managedsimilarly to those with idiopathic aplastic anemia

  13. Notableexceptions include patients who receive high doses of cytotoxicchemotherapy drugs: • cytotoxicchemotherapy drugs • antimetabolites • antimitotics • individuals who have thiopurine methyltransferase deficiency (TPMT)

  14. Viruses • Viral infection sespecially in chronicallyill patients often lead to transient cytopenias but frank aplasticanemia is uncommon

  15. COMMON VIRUS •  Epstein-Barr virus •   Human immunodeficiency virus • B19 parvovirus • Herpesviruses • Non-A, non-B, non-C, non-D, non-E, and non-G hepatitis virus 

  16. severe anemia that occurs in sickle cell anemia patients who are acutely infected withB19 parvovirus

  17. Seronegative hepatitis precedes thediagnosis of aplastic anemia in 3 to 5% of cases and is recognizedas hepatitis-associated aplastic anemia

  18. In most cases the hepatitis resolves spontaneously • however when severe aplastic anemia follows it is often fatal and presents within a few months after the onset of hepatitis

  19. Pregnancy • Pregnancy-associated aplastic anemia is a rare entity • despitenumerous case reports the association is not well understood • The onset of aplastic anemia can occur during pregnancy or shortly after delivery

  20. In contrast to idiopathic aplastic anemia, pregnancyassociatedaplastic anemia is often associated with spontaneousremissions • in patients with severe disease therapyshould be initiated promptly since maternal and fetal mortalityare not uncommon

  21. PATHOPHYSIOLOGY • Autoimmunity • Stem Cell • Clonality

  22. cytotoxic T lymphocytes were found to mediate the destruction ofhematopoietic stem cells in aplastic anemia

  23. Stem Cells • reduction in the number of hematopoietic stem/progenitor cellsis a universal laboratory finding in aplastic anemia • C034 + cells assayable hematopoietic and long-term culture-initiatingcells are strikingly reduced in aplastic anemia

  24. CLINICAL FEATURES • Clinical manifestations are proportional to theperipheral blood cytopenias and include: • dyspnea on exertion fatigue • easy bruising petechia epistaxis gingival bleeding heavy menses headache • fever

  25. complete blood count • reticulocyte count • bone marrow aspirate and biopsy • Cytogenetic study • Flowcytometry

  26. BM Aspiration BM Biopsy

  27. Patientsyounger than 40 years of age should be screened for Fanconi anemia • using the clastogenic agents diepoxybutane and mitomycin Cthat test for increased chromosomal breakage

  28. A hypocellular bone marrow is required for the diagnosis ofaplastic anemia

  29. Classification Acquired aplastic anemia is classified as: • non severeAA • severeAA • very severeAA • based onthe degree of peripheral blood pancytopenia

  30. Classification of Aplastic Anemia • severe aplastic anemia • Bone marrow cellularity <25% • Two of three peripheral blood criteria: • Absolute neutrophil count <500/mm3 • Platelet count <20,OOO/mm3 • Reticulocyte count <60,OOO/mm3 or < 1% corrected reticulocyte count • Very severe aplastic anemia (VSAA) • Same as SAAwith absolute neutrophil count <200/mm3 • Nonsevere (moderate) aplastic anemia • Bone marrow cellularity <25% • Peripheral blood cytopenias do not fulfill criteria for SAA

  31. SUPPORTIVE CARE • Patients with symptomatic anemia and/or thrombocytopeniaassociated with wet purpura or bleeding require immediate bloodtransfusions

  32. All transfusions in patients with suspected aplastic anemia should be irradiated to prevent transfusion-associatedgraft versus host disease

  33. If the patient is a potential BMTcandidate and is cytomegalovirus negative theCMVstatusis unknown • CMV transmission should be avoided by : • Either leukoreduction • or the use of CMV-negative products

  34. Blood donationfrom family members should be avoided to prevent alloimmunization that could also complicate future BMT

  35. Antibiotic • Overwhelming sepsis caused by bacteria or fungus (especiallyAspergillus) • is the most frequent cause of death from aplasticanemia

  36. In most circumstances prophylactic antibiotics are unnecessary • for patients with absolute neutrophil counts thatare consistently <200 prophylaxis with oral antibiotics such as a: • quinolone • triazole antifungal is reasonable

  37. Patientswith febrile neutropenia should be treated promptly with broadspectrum Antibiotics • In patients with persistent fever after the initiationof antibacterial antibioticsAspergillus coverage should be added

  38. Prophylaxis for Pneumocystis carinii pneumonia should begiven to all patients for at least 6 months after: • immunosuppressivetherapy • BMT • high-dose cyclophosphamidetherapy

  39. Growth Factors Hematopoietic growth factor deficiencysuch as • Erythropoietin • granulocyte • colony-stimulating factor • thrombopoietin • granulocytemonocytecolony-stimulating factor is not responsible for the bonemarrow failure in aplastic anemia

  40. Patients with moresignificant cytopeniassuch as symptomatic anemia may benefit from a trial of : • immunosuppressive therapy with anti thymocyteglobulin and cyclosporine (ATG/CSA) • CSA alone

  41. Bone Marrow Transplantation • Allogeneic BMT from an HLA-matched sibling donor is the treatmentof choice at most centers for young patients with SAA

  42. Immunosuppressive TherapyImmunosuppressive therapy with • Immunosuppressive therapy with ATG/CSA is used in patientswho are not candidates for bone marrow transplantation • becauseof older age or lack of a matched sibling donor

More Related